Cedar Mountain Advisors
ACAD icon

Cedar Mountain Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

Cedar Mountain Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$6.21K Hold
308
– – ﹤0.01% 593
2026
Q2 		$7.79K Hold
308
– – ﹤0.01% 565
2026
Q1 		$6.86K Buy
+308
New +$7.36K ﹤0.01% 557

Other funds holding ACAD

Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
State of Alaska Department of Revenue
State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return
Louisiana State Employees Retirement System
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.56B AUM 41.43% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return
Yousif Capital Management
Yousif Capital Management Bloomfield Hills, Michigan $8.87B AUM 34.1% 1-Year Est. Return
Amalgamated Bank
Amalgamated Bank New York $14.3B AUM 35.81% 1-Year Est. Return
Gradient Investments
Gradient Investments Arden Hills, Minnesota $7B AUM 14.85% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Cedar Mountain Advisors's ACAD Position: Q3 2026 in Review

Cedar Mountain Advisors held its Acadia Pharmaceuticals (ACAD) position steady in Q3 2026 at 308 shares worth $6.21K. The position accounts for ﹤0.01% of the portfolio, ranked #593.

Cedar Mountain Advisors first reported a position in ACAD in Q1 2026 and has held it in 3 quarters since. The position peaked at $7.79K in Q2 2026. 46 funds tracked by Wall St. Rank hold ACAD as of Q3 2026.

  • Cedar Mountain Advisors held 308 shares of Acadia Pharmaceuticals worth $6.21K as of Q3 2026.
  • Cedar Mountain Advisors left its Acadia Pharmaceuticals share count unchanged in Q3 2026.
  • Acadia Pharmaceuticals made up ﹤0.01% of Cedar Mountain Advisors's portfolio in Q3 2026, its #593 holding.
  • Cedar Mountain Advisors first reported a position in Acadia Pharmaceuticals in Q1 2026 and has held it in 3 quarters since.
  • Cedar Mountain Advisors's Acadia Pharmaceuticals position peaked at $7.79K in Q2 2026.
  • 46 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2026.

Based on Cedar Mountain Advisors's 13F filing for Q3 2026, filed 15 Oct 2026.